The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo

समान संसाधन

• Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat)
  द्वारा: Furlan, Antonio, और अन्य
  प्रकाशित: (2011)
• The Oral Histone Deacetylase Inhibitor ITF2357 Reduces Cytokines and Protects Islet β Cells In Vivo and In Vitro
  द्वारा: Lewis, Eli C, और अन्य
  प्रकाशित: (2011)
• The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines
  द्वारा: Leoni, Flavio, और अन्य
  प्रकाशित: (2002)
• The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4+ T-Cells and Monocytes and is Superior to Valproic Acid for Latent HIV-1 Expression in Vitro
  द्वारा: Matalon, Shay, और अन्य
  प्रकाशित: (2010)
• Specific Inhibition of Histone Deacetylase 8 Reduces Gene Expression and Production of Proinflammatory Cytokines in Vitro and in Vivo
  द्वारा: Li, Suzhao, और अन्य
  प्रकाशित: (2015)